Breaking News
Get 40% Off 0
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks
Close

Myovant Sciences Ltd (MYOV)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Myovant Sciences's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
Myovant Sciences historical data, for real-time data please try another search
26.98 0.00    0.00%
09/03 - Closed. Currency in USD ( Disclaimer )
  • Volume: 0
  • Bid/Ask: 26.96 / 27.01
  • Day's Range: 26.98 - 27.00
Type:  Equity
Market:  United States
Myovant Sciences 26.98 0.00 0.00%

NYSE:MYOV Financials

 
This summary provides an overview of the most significant critical numbers from each of the Myovant Sciences Ltd financial reports, including theMyovant Sciences Ltd income statement, balance sheet, and cash flow statement. Additionally, it features several financial ratios that provide insight into the company's financial health.

Investors can select to view data from four periods of either annual or quarterly information, allowing them to track the NYSE:MYOV financials over time via breakdowns of their annual reports.

Myovant Sciences Ltd. reported earnings results for the third quarter and nine months ended December 31, 2022. For the third quarter, the company reported revenue was USD 100.23 million compared to USD 54.44 million a year ago. Net loss was USD 57.63 million compared to USD 63.45 million a year ago. Basic loss per share from continuing operations was USD 0.59 compared to USD 0.68 a year ago.For the nine months, revenue was USD 321.55 million compared to USD 173.41 million a year ago. Net loss was USD 124.49 million compared to USD 146.7 million a year ago. Basic loss per share from continuing operations was USD 1.29 compared to USD 1.59 a year ago.

AnnualQuarterly  
InvestingPro Advanced Financial Summary
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

MYOV Income Statement & Profits

Gross margin TTM -
Operating margin TTM -
Net Profit margin TTM -
Return on Investment TTM -
 Total Revenue  Net Income
Period Ending: Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Total Revenue 100.23 104.82 116.49 57.57
Gross Profit 66 50.55 69.67 110.52
Operating Income -51.9 -33.71 -9.36 -51.94
Net Income -57.63 -45.62 -21.24 -59.28

MYOV Balance Sheet

Quick Ratio MRQ -
Current Ratio MRQ -
LT Debt to Equity MRQ -
Total Debt to Equity MRQ -
 Total Assets  Total Liabilities
Period Ending: Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Total Assets 403.52 483.97 460.13 520.01
Total Liabilities 961.66 997.22 943.65 993.49
Total Equity -558.14 -513.25 -483.52 -473.48

%ENGLISH_NAME% Latest Cash Flow Statement

Cash Flow/Share TTM -
Revenue/Share TTM -
Operating Cash Flow  -41.87%
 Cash  Net Change in Cash
Period Ending: Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Period Length: 0 Months 0 Months 0 Months 0 Months
Cash From Operating Activities -102.9 9.12 -76 -100.09
Cash From Investing Activities 5.26 3.51 -5.74 42.29
Cash From Financing Activities 1.57 3.95 1.19 6.76
Net Change in Cash -96.07 16.58 -80.56 -51.04
* In Millions of USD (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

MYOV Price Commentary

Write your thoughts about Myovant Sciences Ltd
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Koo Wei
Koo Wei Jan 03, 2022 19:57
Saved. See Saved Items.
This comment has already been saved in your Saved Items
1. Great fundamentals a) Great Product - 2 approved life saving/changing blockbusters and another pending. Featured in New England of Medicine which is a big deal. Not going into technical but many doctors and client attested to the benefits and the increasing scripts speaks of itself. Adoption rate and reviews are good. PDUFA for 3rd blockbuster in May 22. partial clinical hold for SERENE trial is recently removed by FDA b) strong financials - huge cash runway of $6b+ cash for a $1.4b-1.5b market capital company with incoming streams of income from tiered payments and commercialising sales of 2 great products. Great leaps in price to sales ratio (value) and also enterprise value to EBITA (growth) Q to Q. Sales going strong and positive affirmation on drugs. Estimated Q1 Earnings is 3983% YOY c) Experienced Pfizer commercialising the above drugs.. acknowledging the value with 4.2b tiered payment.. Pfizer taking this on also speaks vol
Koo Wei
Koo Wei Dec 07, 2021 18:55
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Sumitomo is forced to offset its patent cliff in 2023, making Myovant a hot buyout target. The buyout speculation peaked, when Sumitomo announced the acquisition of Urovant Sciences. With the acquisition of Urovant, Myovant is the only out of 5 vant companies not wholly-owned by Sumitomo.
Koo Wei
Koo Wei Dec 07, 2021 18:28
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Looking at MYOV… potential buyout with 2 drugs approved and 1 upcoming… commercialisation undertaken by Pfizer…. All stars aligned… heavily undervalued
Koo Wei
Koo Wei Dec 06, 2021 18:18
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Buy out the float and force a buyout from the bullies
Koo Wei
Koo Wei Dec 06, 2021 17:44
Saved. See Saved Items.
This comment has already been saved in your Saved Items
underdog taken down by giants through manipulation. 2 blockbuster drugs commercialising and cash on hand… just to buy up the Low float and it’s up up be away…
Nabeel Qabane
Nabeel Qabane Dec 18, 2020 20:48
Saved. See Saved Items.
This comment has already been saved in your Saved Items
why price down after fda approved
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email